Figure 8. VC stimulates TET activity to enhance tumor-infiltrating lymphocytes and efficiency of adoptive T cell therapy.

(A) VC enhanced the adoptive T cell immunotherapy. Kaplan-Meier survival curves for mice injected with WT or Tet2-KO B16-OVA cells and treated with adoptive T cell immunotherapy and VC (sodium ascorbate) as indicated are shown. A quantity of 2 × 10⁵ WT or Tet2-KO B16-OVA cells, 5 × 10⁶ OT-I cells, and sodium ascorbate were injected s.c., i.v., and i.p., respectively, into C57BL/6 mice at the indicated time points. Kaplan-Meier survival curves for these mice are shown (n = 10 mice for each group). The survival curve of mice injected with only WT or Tet2-KO B16-OVA cells without treatment in Figure 1D is also shown by a dashed gray or pink line for reference. The P value was determined using log-rank (Mantel-Cox) test, comparing every 2 groups, shown in the table of the figure. *P < 0.05, **P < 0.01, ***P < 0.001. (B) VC enhanced tumor-infiltrating lymphocytes with adoptive T cell immunotherapy. CD8 immunostaining of Tet2-WT and -KO tumor from A treated with adoptive T cell immunotherapy and VC is shown. Scale bars: 200 μm. (C) Quantification of CD8⁺ and CD3⁺ T cells from B and Supplemental Figure 7B. Average cell number per high-power field (HPF) is shown, with 5 HPFs calculated from each group. *P < 0.05, **P < 0.01, ***P < 0.001. The quantification of CD8⁺ and CD3⁺ T cells of mice injected with OT-I cells in Figure 2, D and E, is also shown for reference. Error bars represent ± SD.